ARTV — ARTIVA BIOTHERAPEUTICS INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying ARTV?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 1 buying vs 1 selling last quarter
37
Macro Tailwind
Macro conditions are a headwind for this sector
38
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their ARTV position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Izzy Englander)
  • +3 tracked investors reported holding ARTV at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.

About ARTIVA BIOTHERAPEUTICS INC (ARTV)

ARTIVA BIOTHERAPEUTICS INC (ARTV) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $25M. Across recent filings, tracked investors recorded 4 new positions, 3 increased, 3 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in ARTV

58
/100
Mixed Activity
Added / Increased7
Reduced3
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track ARTV

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

ARTV Ownership Composition

How ARTIVA BIOTHERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
98% of tracked value
Institutions
3
tracked investors
Total Reported
$19M
combined 13F value
Types2
  • Other97.7%
  • Multi-Strategy / Quant2.3%
Other(1)
97.7%
Multi-Strategy / Quant(2)
2.3%

Tracked investors currently reporting ARTV

  • Andreas HalvorsenSep 30, 2026
    Viking Global Investors
    Shares
    2.6M
    Value
    $18.5M
    % Portfolio
    0.06%
  • Ken GriffinSep 30, 2026
    Citadel Advisors
    Shares
    16.4K
    Value
    $116.7K
    % Portfolio
    0.00%
  • Izzy EnglanderSep 30, 2026
    Millennium Management
    Shares
    44.5K
    Value
    $316.6K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold ARTV?
3 tracked institutional investors disclosed a position in ARTV (ARTIVA BIOTHERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of ARTV?
Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in ARTV, valued at $25M.
Did institutional ownership of ARTV increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 3 increased, 3 reduced, and 2 fully exited ARTV.
Where does this ARTV ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.